Redx Pharma plc has closed its biggest transaction to date, selling a preclinical KRAS inhibitor program to Jazz Pharmaceuticals plc in a potential $880 million deal. Of that, $10 million will be paid up front, with the balance to come in development and commercialization milestones. For any product that makes it to market, Redx will in addition receive tiered mid-single digit percentage royalties.
SEOUL, South Korea, Feb. 6, 2024 /PRNewswire/ Daewoong Pharmaceutical (KRX: 069620.KS), a global pharmaceutical company located in Seoul, announced its
Doctor issues cold weather advice for respiratory disease patients aol.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from aol.co.uk Daily Mail and Mail on Sunday newspapers.